Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
The views and opinions expressed in this article are those of the author and do not necessarily reflect the views or positions of the Novo Nordisk Foundation
The GLP-1 diabetes treatment drugs market is expected to grow at a 25.3% CAGR between 2025 and 2035
This case illustrates the intersection of benefits and reality: Medicaid began covering an expensive drug (under pharmacy benefit) with hope of future savings, only to confront immediate budget strain
Mounjaro (tirzepatide) uniquely targets both GLP-1 and GIP receptors, potentially offering more substantial weight reduction and improved glycemic control compared to other GLP-1RAs that only target the GLP-1 receptor, such as Ozempic (semaglutide)
This personalized approach can benefit individuals who dont respond well to standard treatments or have specific medical conditions requiring adjustments
